- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CNTO-1959 | Tremfya®
guselkumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Guselkumab is a monoclonal antibody directed against interleukin-23A (IL23A). It is being investigated as a treatment for plaque psoriasis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|No information available.|
|Summary of Clinical Use|
|Having completed Phase III clinical trials for various forms of psoriasis, guselkumab was approved in 2017 for patients with moderate to severe plaque psoriasis. Click here to link to ClinicalTrials.gov's listing of Phase III guselkumab trials.|
|Mechanism Of Action and Pharmacodynamic Effects|
|The cytokine IL23 plays an important role in modulating the immune system. Abberant expression of IL23 has been implicated in the pathogenesis of autoimmune diseases such as psoriasis  and arthritis . Guselkumab neutralises circulating IL23 by binding the IL23A (p19) subunit, and thereby reduces pathological disease symptoms.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)